Analytical Data
-
Gene name
Tnfrsf11b
- Application
-
Alternative Names
Tnfrsf11b；OCIF；Tumor necrosis factor receptor superfamily member 11B
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00300
-
Expression Region
22-401aa
-
AA Sequence
ETFPPKYLHYDEETSHQLLCDKCPPGTYLKQHCTAKWKTVCAPCPDHYYT DSWHTSDECLYCSPVCKELQYVKQECNRTHNRVCECKEGRYLEIEFCLKH RSCPPGFGVVQAGTPERNTVCKRCPDGFFSNETSSKAPCRKHTNCSVFGL LLTQKGNATHDNICSGNSESTQKCGIDVTLCEEAFFRFAVPTKFTPNWLS VLVDNLPGTKVNAESVERIKRQHSSQEQTFQLLKLWKHQNKDQDIVKKII QDIDLCENSVQRHIGHANLTFEQLRSLMESLPGKKVGAEDIEKTIKACKP SDQILKLLSLWRIKNGDQDTLKGLMHALKHSKTYHFPKTVTQSLKKTIRF LHSFTMYKLYQKLFLEMIGNQVQSVKISCL
-
Molecular Weight
44 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Recombinant Tnfrsf11b, also known as osteoprotegerin (OPG), is a key regulator of bone metabolism and plays a crucial role in the pathogenesis of various diseases, including osteoporosis and rheumatoid arthritis. OPG functions as a decoy receptor for receptor activator of nuclear factor-κB ligand (RANKL), preventing RANKL from binding to its receptor RANK on osteoclasts, thus inhibiting osteoclastogenesis and bone resorption. The imbalance between RANKL and OPG levels leads to increased bone loss and has been implicated in the progression of bone-related disorders. As a result, the development of recombinant OPG has garnered significant attention for its therapeutic potential. Research has focused on optimizing its expression, purification, and functional characterization to enhance its efficacy. By utilizing recombinant DNA technology, researchers can produce a stable and active form of Tnfrsf11b for investigation in preclinical and clinical settings. Furthermore, understanding the molecular mechanisms underlying OPG's interactions with RANKL and its downstream signaling pathways is essential for developing targeted therapies that can effectively manage bone metabolism-related diseases. Overall, advances in recombinant Tnfrsf11b research hold promise for improving treatment strategies in bone health and addressing the challenges posed by degenerative bone diseases.
